Buyrimonabant.co.uk |
|
Smoking Cessation and Acomplia Rimonabant
Rimonabant acomplia may also be found to effective in assisting
some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to
determine the possible value of rimonabant in smoking-cessation therapy. The
Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than
6,000 subjects. STRATUS is designed to explore two smoking-related therapies.
First, to use rimonabant directly to aid in smoking cessation. Second, to help
prevent weight gain in former smokers. Initial results apparently suggest that
rimonabant is effective for both uses. However, the FDA has explicitly stated to
Sanofi-Aventis that without additional studies rimonabant cannot be approved in
the United States for smoking cessation therapy.
References
^ Despres JP, Golay A, Sjostrom L Effects
of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
N Engl J Med. 2005 Nov 17;353(20):2121-34. Entrez PubMed 16291982
^ Van Gaal LF, Rissanen AM, Scheen AJ,
Ziegler O, Rossner S Effects of the cannabinoid-1 receptor blocker rimonabant on
weight reduction and cardiovascular risk factors in overweight patients: 1-year
experience from the RIO-Europe study Lancet. 2005 Apr 16-22;365(9468):1389-97.
Entrez PubMed 15836887
|